- Home
- AEON vs KZIA Comparison
AEON vs KZIA Comparison
Compare AEON & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- KZIA
- Stock Information
- Founded
- AEON N/A
- KZIA 1994
- Country
- AEON United States
- KZIA Australia
- Employees
- AEON N/A
- KZIA N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- KZIA Health Care
- Exchange
- AEON Nasdaq
- KZIA Nasdaq
- Market Cap
- AEON 8.0M
- KZIA 9.0M
- IPO Year
- AEON N/A
- KZIA 1999
- Fundamental
- Price
- AEON $0.76
- KZIA $8.01
- Analyst Decision
- AEON Strong Buy
- KZIA Strong Buy
- Analyst Count
- AEON 1
- KZIA 2
- Target Price
- AEON $360.00
- KZIA $14.00
- AVG Volume (30 Days)
- AEON 77.0K
- KZIA 137.6K
- Earning Date
- AEON 11-12-2025
- KZIA 11-14-2025
- Dividend Yield
- AEON N/A
- KZIA N/A
- EPS Growth
- AEON N/A
- KZIA N/A
- EPS
- AEON N/A
- KZIA N/A
- Revenue
- AEON N/A
- KZIA $1,549,158.00
- Revenue This Year
- AEON N/A
- KZIA N/A
- Revenue Next Year
- AEON N/A
- KZIA $49.25
- P/E Ratio
- AEON N/A
- KZIA N/A
- Revenue Growth
- AEON N/A
- KZIA 248983.08
- 52 Week Low
- AEON $0.38
- KZIA $2.86
- 52 Week High
- AEON $115.57
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- AEON 50.51
- KZIA 49.61
- Support Level
- AEON $0.73
- KZIA $7.60
- Resistance Level
- AEON $0.81
- KZIA $8.88
- Average True Range (ATR)
- AEON 0.06
- KZIA 0.53
- MACD
- AEON 0.00
- KZIA 0.04
- Stochastic Oscillator
- AEON 56.52
- KZIA 36.03
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.